Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome

NCT04313881 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04313881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04313881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Terminated
Start date
September 9, 2020
Completion date
September 13, 2023
Enrollment
539 (actual)
Sites
169

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes